Clinical development of talimogene laherparepvec (T-VEC): A modified herpes simplex virus type-1-derived oncolytic immunotherapy

Expert Review of Anticancer Therapy

Volumn 15, Issue 12, 2015, Pages 1389-1403

  Harrington, Kevin J ^a   Puzanov, Igor ^a   Hecht, J Randolph ^b   Hodi, F Stephen ^c   Szabo, Zsolt ^d   Murugappan, Swami ^d   Kaufman, Howard L ^e  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d AMGEN INC   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

GM CSF; Immune checkpoint inhibitors; Immunotherapy; Intralesional therapy; Melanoma; Oncolytic virus; Talimogene laherparepvec

Indexed keywords

ALPHA2B INTERFERON; AMYLASE; ATEZOLIZUMAB; BCG VACCINE; BEVACIZUMAB; CG 0070; CISPLATIN; CVA 21; DABRAFENIB; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; K 901; NIVOLUMAB; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; PELAREOREP; PEMBROLIZUMAB; PEPTIDE VACCINE; PEXASTIMOGENE DEVACIREPVEC; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; ROSE BENGAL; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TRAMETINIB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADVANCED CANCER; AMYLASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELLULITIS; CHEMORADIOTHERAPY; CHILL; COLITIS; COLORECTAL CANCER; CONSTIPATION; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENDOCRINE DISEASE; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEVER; FLU LIKE SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEADACHE; HUMAN; HYPOPHYSITIS; INFLAMMATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LIMB PAIN; LIVER CELL CARCINOMA; LIVER METASTASIS; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PAIN; PANCREAS CANCER; PERIPHERAL EDEMA; PNEUMONIA; PRURITUS; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TRIPLE NEGATIVE BREAST CANCER; TUMOR IMMUNITY; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; VOMITING; ADVERSE EFFECTS; ANIMAL; COMPARATIVE STUDY; GENETICS; HERPES SIMPLEX VIRUS 1; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN NEOPLASMS; VIROLOGY;

ANIMALS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM STAGING; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS;

EID: 84949200961     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1115725     Document Type: Article

References (67)

1. Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013; 10 (10): 588-598.
2. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17 (7): 2105-2116.
3. Maverakis E, Cornelius LA, Bowen GM, et al. Metastatic melanoma-a review of current and future treatment options. Acta Derm Venereol. 2015; 95 (5): 516-524.
4. Sloot S, Rashid OM, Zager JS. Intralesional therapy for metastatic melanoma. Expert Opin Pharmacother. 2014; 15 (18): 2629-2639.
5. Tronnier M, Mitteldorf C. Treating advanced melanoma: current insights and opportunities. Cancer Manag Res. 2014; 6: 349-356.
6. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011; 29 (22): 3085-3096.
7. Ahronian LG, Sennott EM, Van Allen EM, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 2015; 5 (4): 358-367.
8. Aris M, Barrio MM. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol. 2015; 6: 46.
9. Azijli K, Stelloo E, Peters GJ, et al. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res. 2014; 34 (4): 1493-1505.
10. Srivastava N, McDermott D. Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res. 2014; 6: 279-289.
11. Bristol-Myers Squibb Company. YERVOY® (ipilimumab) prescribing information. 2013.
12. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364 (26): 2517-2526.
13. Hodi FS, ODay SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363 (8): 711-723.
14. Tsai KK, Daud AI. The role of anti-PD-1/PD-L1 agents in melanoma: progress to date. Drugs. 2015; 75 (6): 563-575.
15. Brystol-Myers Squibb Company. OPDIVO (nivolumab) prescribing information. 2014.
16. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384 (9948): 1109-1117.
17. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372 (26): 2521-2532.
18. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372 (4): 320-330.
19. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372 (21): 2006-2017.
20. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. J Clin Oncol. 2014; 32 (5S): Abstract 5009.
21. Hammers HJ, Plimack ER, Infante JR, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014; 32 (5S): Abstract 4504.
22. Kaufman HL, Ruby CE, Hughes T, et al. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014; 2: 11.
23. Weide B, Eigentler TK, Pflugfelder A, et al. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol Res. 2014; 2 (7): 668-678.
24. Thompson JF, Agarwala SS, Smithers BM, et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015; 22 (7): 2135-2142.
25. Parato KA, Senger D, Forsyth PA, et al. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005; 5 (12): 965-976.
26. Forbes NE, Krishnan R, Diallo JS. Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses. Front Oncol. 2014; 4: 191.
27. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012; 30 (7): 658-670.
28. Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015; 33 (25): 2780-2788.
29. Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 2006; 13 (11): 975-992.
30. Fukuhara H, Todo T. Oncolytic herpes simplex virus type 1 and host immune responses. Curr Cancer Drug Targets. 2007; 7 (2): 149-155.
31. Lim F, Khalique H, Ventosa M, et al. Biosafety of gene therapy vectors derived from herpes simplex virus type 1. Curr Gene Ther. 2013; 13 (6): 478-491.
32. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10 (4): 292-303.
33. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol. 2002; 3 (1): 17-26.
34. Pol JG, Rességuier J, Lichty BD. Oncolytic viruses: a step into cancer immunotherapy. Virus Adapt Treat. 2012; 4: 1-21.
35. Melcher A, Parato K, Rooney CM, et al. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther. 2011; 19 (6): 1008-1016.
36. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene. 2003; 22 (20): 3188-3192.
37. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006; 12 (22): 6737-6747.
38. Chang KJ, Senzer NN, Binmoeller K, et al. Phase I dose-escalation study of talimogene laherparepvec (T-VEC) for advanced pancreatic cancer (ca). J Clin Oncol. 2012; 30 (Suppl): Abstract e14546.
39. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010; 16 (15): 4005-4015.
40. PR Newswire. Amgen Press Release. 2011 [cited 2015 Aug 3]. Available from: http://wwwext.amgen.com/media/media-pr-detail.jspyear=2011&releaseID=1590733.
41. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009; 27 (34): 5763-5771.
42. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010; 17 (3): 718-730.
43. Senzer NN, Bedell C, Horvath S, et al. Systemic benefit of GM-CSF-Encoding, oncolytic herpes virus (talimogene laherparepvec, T-VEC) in metastatic melanoma: phase II assessment. Ann Oncol. 2014; 25 (Suppl 4): Abstract 1059P.
44. Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010; 6 (6): 941-949.
45. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2000; 18 (8): 1614-1621.
46. Nemunaitis JJ, Andtbacka RH, Ross M, et al. Results of the extension trial of OPTiM, a multicenter, randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs GM-CSF for unresected stage IIIB-IV melanoma. Ann Oncol. 2014; 25 (Suppl 4): Abstract 1102P.
47. Wolchok JD, Hoos A, ODay S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15 (23): 7412-7420.
48. Ross MI, Andtbacka RHI, Puzanov I, et al. Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): results from a phase III trial in patients with stage IIIb-IV melanoma. J Clin Oncol. 2014; 32 (Suppl 5S): Abstract 9026.
49. Andtbacka RHI, Ross MI, Delman K, et al. Responses of injected and uninjected lesions to intralesional talimogene laherparepvec (T-VEC) in the OPTiM study and the contribution of surgery to response. Society of Surgical Oncology Annual Cancer Symposium; 2014 Mar 12-15; Phoenix, AZ. Abstract 52.
50. Andtbacka RH, Collichio FA, Amatruda T, et al. Final planned overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). J Immunother Cancer. 2014; 2 (Suppl 3): Abstract P263.
51. Duraiswamy J, Kaluza KM, Freeman GJ, et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013; 73 (12): 3591-3603.
52. Zamarin D, Postow MA. Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther. 2015; 150: 23-32.
53. Lichty BD, Breitbach CJ, Stojdl DF, et al. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014; 14 (8): 559-567.
54. Puzanov I, Milhem MM, Andtbacka RHI, et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol. 2014; 32 (5s): Abstract 9029.
55. Puzanov I, Milhem M, Andtbacka RHI, et al. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol. 2015; 33 (Suppl): Abstract 9063.
56. FirstWord Pharma. Amgen Press Release. 2015 [cited 2015 Jun 24]. Available from: http://www.firstwordpharma.com/node/1288054tsid=33
57. Piasecki J, Le T, Ponce R, et al. Talimogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade. American Association of Cancer Research Annual Meeting; 2015 Apr 18-22; Pennsylvania, PH; Abstract 258.
58. Ribas A, Puzanov I, Gajewski TF, et al. A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma. J Clin Oncol. 2015; 33 (Suppl): Abstract 9063.
59. PR Newswire. Amgen Press Release. 2015 [cited 2015 Jun 25]. Available from: http://www.amgen.com/media/media-pr-detail.jspreleaseID=2054439.
60. Laoui D, Van OE, De BP, et al. Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression. Front Immunol. 2014; 5: 489.
61. Schaer DA, Cohen AD, Wolchok JD. Anti-GITR antibodies-potential clinical applications for tumor immunotherapy. Curr Opin Investig Drugs. 2010; 11 (12): 1378-1386.
62. Andtbacka RHI, Chastain M, Li A, et al. Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL) (NCT02211131). J Clin Oncol. 2015; 33 (Suppl): Abstract TPS9094.
63. Ashworth MT, Daud AI. Combinatorial approach to treatment of melanoma. Hematol Oncol Clin North Am. 2014; 28 (3): 601-612.
64. Barker CA, Postow MA. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys. 2014; 88 (5): 986-997.
65. Nishino M, Giobbie-Hurder A, Ramaiya NH, et al. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer. 2014; 2 (1): 40.
66. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009; 27 (16): 2645-2652.
67. Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014; 2 (7): 632-642.